IP Library › Granted Patent US 12,226,378
Granted Patent B2
US 12,226,378 · App. 18/049,983 · Granted Feb 18, 2025

Topical substance for vaginal use

Inventor: Wendy Strgar (Eugene, OR)
Assignee: VAGINAL BIOME SCIENCE, INC.
A61K31/191A61K9/00A61K9/0034A61K9/06A61K47/02A61K47/12A61K47/36A61K47/38G01N33/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,378
App. No.
18/049,983
Granted
Feb 18, 2025
Kind
B2
Abstract

Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.

Claims (41)

1. A topical substance for vaginal use, the topical substance comprising:

a solvent;

a viscosity modifier;

at least one salt; and

from 0.2 to 2% by weight of lactic acid which is a mixture of a D-lactic acid and a L-lactic acid,

wherein the topical substance has an osmolality from 100 mOsm/Kg to 500 mOsm/Kg and a pH from 3.0 to 6.0.

2. The topical substance according to claim 1 , wherein the lactic acid has a racemic index from about 30 L/70 D to about 70 L/30 D.

3. The topical substance according to claim 1 , wherein the lactic acid has a racemic index of about 50 L/50 D.

4. The topical substance according to claim 1 , wherein the topical substance is isotonic with human vaginal fluid.

5. The topical substance according to claim 1 , wherein the topical substance is in a form selected from the group consisting of a gel, a cream, a lubricant, an ointment, and a suppository.

6. The topical substance according to claim 1 , wherein the pH of the topical substance is from 3.0 to 5.0.

7. The topical substance according to claim 1 , wherein the pH of the topical substance is from 3.0 to 4.5.

8. The topical substance according to claim 1 , wherein the topical substance comprises:

from 0.002 to 1.6% by weight of potassium salt; and

from 0.1 to 1.5% by weight of sodium salt,

wherein a racemic index of the lactic acid is from about 20 L/80 D to about 80 L/20 D and the topical substance has a pH from 3.0 to 5.0.

9. The topical substance according to claim 8 , wherein the topical substance further comprises from 0.005 to 0.12% by weight of calcium salt.

10. A method for manufacturing a topical substance that is isotonic with healthy human vaginal fluids, the method comprising adding into a solvent, a viscosity modifier, a plurality of salts, and one or more acid,

wherein the one or more acid is lactic acid that is a mixture of a D-lactic acid and a L-lactic acid and added at an amount from 0.2 to 2% by weight of the topical substance,

the topical substance has a pH from 3.0 to 5.0, and

an osmolality of the topical substance is from 100 mOsm/Kg to 500 mOsm/Kg.

11. The method of claim 10 , wherein the lactic acid has a racemic index of from 30 L/70 D to 70 L/30 D.

12. The method of claim 10 , wherein the lactic acid has a racemic index of about 50 L/50 D.

13. The method of claim 10 , wherein the pH of the topical substance is from 3.0 to 4.5.

14. The method of claim 10 , wherein the plurality of salts comprises:

from 0.002 to 1.6% by weight of potassium salt;

from 0.1 to 1.5% by weight of sodium salt; and

wherein a racemic index of the lactic acid is from about 20 L/80 D to about 80 L/20 D and the topical substance has a pH from 3.0 to 5.0.

15. The method of claim 14 , wherein the plurality of salts further comprises from 0.005 to 0.12% by weight of calcium salt.

16. A method for improving lubrication of a vagina of a subject in need thereof, comprising applying an effective amount of the topical substance in the form of the lubricant according to claim 5 to the vagina of the subject, wherein the applied amount is effective so as to increase the lubrication in the vagina of the subject compared with that of a subject that has not been administered the topical substance.

17. A method for improving vaginal moisture of a subject in need thereof, comprising applying an effective amount of the topical substance according to claim 1 to the vagina of the subject, wherein the applied amount is effective so as to increase the moisture in the vagina of the subject compared with that of a subject that has not been administered the topical substance.

18. The method according to claim 16 , wherein a pH of a vaginal fluid of the subject after applying the topical substance is from 3.0 to 6.0, and the osmolality of the fluid is 100 mOsm/Kg to 500 mOsm/Kg.

19. The method according to claim 17 , wherein a pH of a vaginal fluid of the subject after applying the topical substance is from 3.0 to 6.0, and the osmolality of the fluid is 100 mOsm/Kg to 500 mOsm/Kg.

20. A method for improving a vaginal biome of a subject in need thereof, comprising applying an effective amount of the topical substance according to claim 1 ,

wherein the applied amount is effective so as to increase a proportion of D-lactic acid within a total lactic acid produced by the vaginal biome or reduce a pH of a vaginal fluid of the subject as compared with a vagina of a subject that has not been administered the topical substance.

21. A method for maintaining a healthy vaginal biome of a subject, comprising applying an effective amount of the topical substance according to claim 1 to the vagina of the subject,

wherein the vaginal biome of the subject produces lactic acid having a proportion of D-lactic acid higher than 20%, and a pH of a vaginal fluid of the subject is from 3.0 to 4.5.

22. A method for reducing a risk of developing at least one condition selected from the group consisting of bacterial vaginosis, vaginal dysbiosis, and an unhealthy vaginal condition; or reducing a susceptibility to sexually transmitted infection of a subject, comprising applying an effective amount of a topical substance with components of healthy human vaginal fluids to a vagina of a subject in need thereof,

wherein a vaginal biome of the subject after applying the topical substance produces lactic acid having a higher proportion of D-lactic acid compared with a subject that has not been administered the topical substance; or a vaginal fluid of the subject has a lower pH compared with the subject that has not been administered the topical substance; and

the subject administered the topical substance has a lower risk of developing at least one condition selected from the group consisting of bacterial vaginosis, vaginal dysbiosis, and an unhealthy vaginal condition; or a reduced susceptibility to sexually transmitted infection compared with a subject that has not been administered the topical substance,

wherein in the unhealthy vaginal condition, the vaginal biome of the subject produces lactic acid having a proportion of D-lactic acid lower than 20% of a total lactic acid or the pH of the vaginal fluid of the subject is higher than 4.5.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2022
From: GOOD CLEAN LOVE, INC.
To: VAGINAL BIOME SCIENCE, INC.
Reel/Frame 061806/0834 →
Continuity (7)
Continuation 17209252 · Mar 23, 2021
Continuation 16191292 · Nov 14, 2018
Continuation In Part 15691645 · Aug 30, 2017
Continuation In Part 15294340 · Oct 14, 2016
Continuation 14636035 · Mar 2, 2015
Provisional Application 62094769 · Dec 19, 2014
Related Publication 20230070915A1 · Mar 9, 2023
References Cited (45)
US 5466463A · Ford · 1995 [cited by applicant]
US 5765579A · Heiler et al. · 1998 [cited by applicant]
US 5778886A · Shihata · 1998 [cited by applicant]
US 6045786A · Cone et al. · 2000 [cited by applicant]
US 6892732B2 · Wang et al. · 2005 [cited by applicant]
US 8367098B2 · Maguire et al. · 2013 [cited by applicant]
US 9470676B2 · Strgar · 2016 [cited by examiner]
US 10195169B2 · Strgar · 2019 [cited by examiner]
US 10357527B2 · Ellington et al. · 2019 [cited by applicant]
US 10952979B2 · Strgar · 2021 [cited by examiner]
US 11806325B2 · Strgar · 2023 [cited by examiner]
US 20030039944A1 · Grueneberg et al. · 2003 [cited by applicant]
US 20040132690A1 · Carmelia et al. · 2004 [cited by applicant]
US 20090105314A1 · Ii et al. · 2009 [cited by applicant]
US 20120195961A1 · Kritikou · 2012 [cited by applicant]
US 20140147520A1 · Gupta et al. · 2014 [cited by applicant]
CN 1113150 · 1995 [cited by applicant]
CN 101559036 · 2009 [cited by applicant]
CN 101773513 · 2010 [cited by applicant]
CN 102512338 · 2012 [cited by applicant]
CN 102266283 · 2012 [cited by applicant]
EP 1582186 · 2005 [cited by applicant]
EP 2018872 · 2009 [cited by applicant]
JP 03264520 · 1991 [cited by applicant]
JP 101430 · 1998 [cited by applicant]
KR 20090054777 · 2009 [cited by applicant]
WO 2001095951 · 2001 [cited by applicant]
WO 2006075236 · 2006 [cited by applicant]
WO 2014152154 · 2014 [cited by applicant]
Aroutcheva, et al., “Defense Factors of Vaginal Lactobacilli,” Am. J. Obstet Gynecol, 2001, vol. 185(2), pp. 375-379. [cited by applicant]
Ayehunie, et al., “Hyperosmolal Vaginal Lubricants Markedly Reduce Epithelial Barrier Properties in a Three-Dimensional Vaginal Epithelium Model,” Toxicology Reports, 2018, vol. 5, pp. 134-140. [cited by applicant]
Balance Activ Vaginal Gel (7×5ml Tubes) Product Information 2013, https:www.expresschemist.co.ukbalance_activ_vaginal_gel.html, pp. 2. [cited by applicant]
Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 18. [cited by applicant]
Gynofit Gel with Lactic Acid, 2010, http://www.gynofit.com/milchsaeure-vaginalgel-en.html, pp. 2. [cited by applicant]
Gynofit Lactic Acid Vaginal Gel 5ml N6 Product Information 2013, http://ww.efarma.it, pp. 3. [cited by applicant]
Manjakani Plus Feminine Wash with Kacip Fatimah, Product Information 2013 https://www.hervsforlove.com, pp. 2. [cited by applicant]
Moench, et al., “Microbicide Excipients Can Greatly Increase Susceptibility to Genital Herpes Transmission in the Mouse,” BMC Infect. Dis., 2010, vol. 10 (331), pp. 9. [cited by applicant]
Natural Ecological Lubricant, Organic Products without Intermediaries, Product Information 2013, https://www.productosecologicossinintermediarios.es, pp. 3. [cited by applicant]
Owen, et al., “A Review of the Physical and Chemical Properties of Human semen and the Formulation of a Semen Simulant,” J. Androl., 2005, vol. 26 (4), pp. 459-469. [cited by applicant]
Owen, et al., “A Vaginal Fluid Simulant,” Contraception, 1999, vol. 59 (2), pp. 91-95. [cited by applicant]
Pre-Seed—Vaginal Lubricant, Product Information 2013, https://www.amazon.co.uk, pp. 6. [cited by applicant]
Rastogi, et al., Engineering and Characterization of Simplified Vaginal and Seminal Fluid Simulants, Contraception, 2016, vol. 93 (4), pp. 337-346. [cited by applicant]
Tien, et al., “In Vitro and in Vivo Characterization of a Potential Universal Placebo Designed for use in Vaginal Microbicide Clinical Trials,” AIDS Res. Hum. Retroviruses, 2005, vol. 21 (10), pp. 845-853. [cited by applicant]
“Vegan Spermicide Alternative”, Product Information 2013, https://vegan-love.com, pp. 7. [cited by applicant]
“Yes Intimate Lubricants”, The Natural Skincare Company, Product Information 2013, https://www.thenaturalskincarecompany.co.k, pp. 4. [cited by applicant]